What Happened?
Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) fell 10.9% in the afternoon session after the company reported disappointing fourth-quarter results: EPS missed analysts' expectations, and sales were underwhelming, coming in line with expectations. We struggled to find many positives in these results, especially because EPS missed. Overall, this quarter could have been better.
The shares closed the day at $318.43, down 11.1% from previous close.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy United Therapeutics? Access our full analysis report here, it’s free .
What The Market Is Telling Us
United Therapeutics’s shares are not very volatile and have only had 7 moves greater than 5% over the last year. Moves this big are rare for United Therapeutics and indicate this news significantly impacted the market’s perception of the business.
United Therapeutics is down 11.5% since the beginning of the year, and at $318.89 per share, it is trading 22.2% below its 52-week high of $410 from November 2024. Investors who bought $1,000 worth of United Therapeutics’s shares 5 years ago would now be looking at an investment worth $3,014.
Today’s young investors likely haven’t read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next .
